These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16127031)

  • 21. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
    Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
    J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.
    Bratu S; Quale J; Cebular S; Heddurshetti R; Landman D
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):196-201. PubMed ID: 15772821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.
    Tsuji BT; Landersdorfer CB; Lenhard JR; Cheah SE; Thamlikitkul V; Rao GG; Holden PN; Forrest A; Bulitta JB; Nation RL; Li J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3913-20. PubMed ID: 27067330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
    Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.
    Cha R; Rybak MJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1067-71. PubMed ID: 15486084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I; Cars O; Löwdin E
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
    Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
    Tam VH; Schilling AN; Poole K; Nikolaou M
    J Antimicrob Chemother; 2007 Dec; 60(6):1302-9. PubMed ID: 17913722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.
    Eagye KJ; Kuti JL; Sutherland CA; Christensen H; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2678-88. PubMed ID: 20110010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.